The market's perception of the pharmaceutical company has undeniably shifted.Even a juggernaut like Eli Lilly (LLY 2.71%) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, signaling that the market's reception to its financial performance was strongly negative.Shareholders discovered that there's reason to believe that a previously hypothesized risk is now real and that it presents a possible threat to ...